Autologous VitD3 tolerogenic monocyte-derived dendritic cell therapy(Fundació Institut D'Investigació Germans Trias I Pujol)(Autologous VitD3 tolerogenic monocyte-derived dendritic cell therapy(Fundació Institut D'Investigació Germans Trias I Pujol))

概要

基本信息

药物类型

细胞疗法

别名-

靶点

VDR

作用机制

VDR激动剂(维生素D受体激动剂)

治疗领域

免疫系统疾病神经系统疾病其他疾病

在研适应症

多发性硬化症

非在研适应症-

原研机构

the Germans Trias i Pujol Research Institute (IGTP)

在研机构

University of NavarraFundación Sociedad Española de Oncologia Medica

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Autologous VitD3 tolerogenic monocyte-derived dendritic cell therapy(Fundació Institut D'Investigació Germans Trias I Pujol) 相关的临床试验

NCT02903537 / Recruiting临床1期IIT

Tolerance-Induction With Dendritic Cells Treated With Vitamin-D3 and Loaded With Myelin Peptides, in Multiple Sclerosis Patients (TOLERVIT-MS)

The purpose of this study is to determine the safety and tolerability of the intranodal administration of autologous monocyte-derived dendritic cells tolerised with Vitamin-D3 and pulsed with myelin peptides (tolDC-VitD3) in multiple sclerosis patients . To select the most appropriate regime for the development of future therapeutic trials.
To evaluate the preliminary proof of concept by clinical and/or radiological activity and immunological markers.

开始日期2017-07-06

申办/合作机构